COVID-19 vaccines

Four vaccines have currently received an authorisation for use in Estonia and Europe. The COVID-19 vaccines are all equally safe, effective and high quality. No concessions were made in the efficacy and safety of the COVID-19 vaccines when they applied for expedited marketing authorisations. The studies and monitoring the safety of the vaccines will continue even after a marketing authorisation has been granted.

Vaccines that have been authorised for use:

Pfizer-BioNTech Comirnaty

Comirnaty is an mRNA vaccine that was granted a conditional marketing authorisation in Europe on December 21.

COVID-19 Vaccine Moderna

Moderna vaccine is an mRNA vaccine that was granted a conditional marketing authorisation in Europe on January 6.

Vaxzevria (COVID-19 Vaccine AstraZeneca)

AstraZeneca vaccine is a viral vector vaccine that was granted a conditional marketing authorization on January 29.

COVID-19 Vaccine Janssen

Janssen vaccine is a viral vector vaccine that was granted a conditional marketing authorization on March 11.

How many and which vaccines have been ordered for Estonia

For buying the vaccines, Estonia is participating in the European Union joint procurement which has been joined by all member states. Altogether, the vaccines of eight vaccine manufacturers are in the European Commission joint procurement portfolio of vaccines. As of right now, Estonia has joined the pre-purchasing agreements with five manufacturers but the government has also given its approval for joining the contracts with other manufacturers.

Along with the Valneva contract that has been added to the joint European Union vaccine portfolio, Estonia has the possibility to acquire 5,229,362 doses altogether, for 2,764,681 people.

Table: “The vaccines in the joint European procurement (the ones that Estonia has already joined are bolded)”
Vaccine	Vaccine type	Marketing authorization or the current state of the application process	How many people it has been ordered for
Pfizer/BioNTech Comirnaty	mRNA	Conditional marketing authorisation from December 21	857 214
Moderna	mRNA	Conditional marketing authorisation from January 6	122 134
Vaxzevria (AstraZeneca)	Adenovirus	Conditional marketing authorisation from January 29	665 000
Janssen Pharmaceutica (Johnson & Johnson)	Adenovirus	Conditional marketing authorisation from March 11	300 000
Curevac	mRNA	No marketing authorisation yet	329 692
Sanofi	Protein-based	No marketing authorisation yet	300 000
Novavax	Protein-based	No marketing authorisation yet	146 542
Valneva	Inactivated	No marketing authorisation yet	44 000

COVID-19 vaccines information

Overview of the vaccines that are currently being reviewed at the European Medicines Agency can be found here.
Read here how COVID-19 vaccines are developed evaluated, approved and monitored.